Polycystic ovary syndrome (PCOS) has been renamed polyendocrine metabolic ovarian syndrome (PMOS) after 14 years of discussions among medical professionals and patient groups. The change, published in *The Lancet*, aims to eliminate confusion surrounding the condition, which affects nearly one in eight women globally. Experts argue that the term PCOS misrepresents the condition, which is not primarily characterized by ovarian cysts. Instead, PMOS encompasses a range of hormone-related issues affecting metabolism, reproductive health, and mental well-being. Symptoms vary widely among individuals, complicating diagnosis and treatment. While PMOS is a leading cause of infertility, many women can still achieve successful pregnancies. Treatment strategies prioritize lifestyle changes, including diet and exercise, alongside medications such as Metformin. The medical community is now focused on raising awareness of the new terminology to facilitate better patient outcomes.